HealthCare Royalty Partners
  • Home
  • Approach
  • Team
  • Portfolio
  • News
  • Contact
  • Investor Login

NEWS

January 7, 2019

Coherus BioSciences Secures $75 Million Credit Financing with HealthCare Royalty Partners

Full Article

November 2, 2018

U.S. FDA Approves UDENYCA™ (pegfilgrastim-cbqv)

Full Article

October 23, 2018

Gary A. Lyons Joins HealthCare Royalty Partners Senior Advisor Board

Full Article

September 25, 2018

Coherus Biosciences Receives European Commission Approval for UDENYCA™ (Pegfilgrastim Biosimilar)

Full Article

May 24, 2018

Portola Pharmaceuticals Receives $100 Million Milestone Payment from HealthCare Royalty Partners for FDA Approval of Andexxa®

Full Article

May 14, 2018

U.S. Food and Drug Administration Accepts and Acknowledges Coherus Biosciences Biologics License Application of CHS-1701 (Pegfilgrastim Biosimilar Candidate) For Review

Full Article

May 10, 2018

La Jolla Pharmaceutical Company Announces $125 Million Royalty Financing Agreement with HealthCare Royalty Partners

Full Article

May 4, 2018

U.S. FDA Approves Portola Pharmaceuticals’ Andexxa®, First and Only Antidote for the Reversal of Factor Xa Inhibitors

Full Article

April 19, 2018

HealthCare Royalty Partners Appoints Four New Partners

Full Article

March 23, 2018

Shingrix approved in Europe and Japan for the prevention of shingles in adults aged 50 and over

Full Article

Page 1 of 11

Next

  • APPROACH
  • TEAM
  • PORTFOLIO
  • NEWS
  • CONTACT
  • INVESTOR LOGIN

LinkedIn Copyright © 2018 HealthCare Royalty Partners | Disclaimer